PubMed Health⌕ Search

Biomedical subjects

A Omodei-Salè

Publications and source records attributed to A Omodei-Salè.

6 recordsLinked to original sources
PubMed1988

Synthesis of some derivatives of 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(piperazin-1-yl)-3-quino linecarbo xylic acid (norfloxacin) as potential antibacterial agents.

Twelve new fluoroquinolones, structurally related to norfloxacin, have been synthesized in order to investigate the effect of substituents at the secondary nitrogen of the piperazine ring on antimicrobial activity. The new substances (carbamates, isoureas, guanidines, ureas and cyanamides) tested on a variety of gram-positive and gram-negative organisms showed lower activity than the model compound.

Anti-Bacterial Agents↗
PubMed1982

DL 111, a new non-hormonal antifertility agent: contragestational and kinetic profile in baboons.

It was previously shown that 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4 triazole (DL 111) given parenterally in single or multiple doses during the early stage of embryonal development terminates pregnancy in the mouse, the hamster, the rat, the rabbit and the dog. In the present work, the studies have been extended to the baboon. In this sub-human primate, single and/or multiple intramuscular injections of the compound terminated pregnancy when given between day 34 and 54 of gestation. The effectiveness of DL 111 was greater when earlier in gestation and the optimal mode of treatment appears to be a multiple one. DL 111 appears to act by a direct action on the conceptus, with consequent suppression of the endocrine function of the placenta, progesterone withdrawal and abortion. In all the baboons that aborted, the menstrual cycles resumed within a reasonable length of time and subsequent cycles were regular. All the animals that did not abort have given birth to normal and health term infants. Fertility appears to be unimpaired and the progeny resulting form these pregnancies did not show any abnormalities. No significant drug-related side-effects or alterations in plasma enzymes or haematological parameters were observed. Pharmacokinetic and activity relationships strongly suggest that sustained exposure of the conceptus to the drug action is indispensable for optimizing the pregnancy-terminating effect.

Abortifacient Agents↗
PubMed1982

Species differences in the disposition and metabolism of 1-methyl-3-(3-pyridyl)-5-(2-hydroxy-methylphenyl)-1H-1,2,4-triazole, a potential sedative-hypnotic compound.

1. Disposition and metabolism of 1-methyl-3-(3-pyridyl)-5-(2-hydroxy-methylphenyl)-1H-1,2,4-triazole, a new sedative-hypnotic, were studied in rats (i.v. and p.o.), cats (i.v.) and human volunteers (p.o.) with 14C-labelled drug. 2. In rat and man, the compound is well absorbed, extensively metabolized, and excreted mostly through the kidney; it has short plasma half-lives, 0.6 h in rat, 0.9 h in man, and 1.9 h in cat. 3. In rat and man metabolism involves N-oxidation of the pyridine ring (Metabolite I), and in cat oxidation of the hydroxymethyl group (Metabolite II). Four other conjugated metabolites (III-VI) isolated from rat urine and bile, and from urine of cats and man, have been characterized. 4. The unchanged compound, but not its metabolites, crosses the blood-brain barrier in rat and cat. 5. The species differences in the disposition and metabolism of the compound are consistent with previous pharmacological data indicating a greater and more prolonged effect in cat.

Adult↗
PubMed1981

A new non-hormonal pregnancy-terminating agent.

DL 111-IT, 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4 triazole, a compound belonging to a new class of non-hormonal antifertility agents, when given subcutaneously, intramuscularly, intravaginally or orally terminates pregnancy in the rat, the mouse, the hamster and the dog. Time-course and dose-activity studies indicate that its effectiveness is dependent on dose, vehicle, route and time of pregnancy. DL 111-IT has no pre-implantation activity. The most effective time for treatment is the early post-implantation period. The compound has an antifertility effect through a slow and continuing action that results in the degeneration and subsequent resorption or expulsion of conceptuses. As a result, there must be sustained availability of active principle to arrest the pregnancy. Administered parenterally in a proper vehicle (oily) and with a suitable schedule of treatment (x 2-5 days), it demonstrates a very high pregnancy terminating activity (ED50: 0.04-0.7 mg/kg/day). Multiple intravaginal and oral administrations are also effective but the daily doses required are 10-20 and 40-100 times higher than the parenteral ones. Studies of the mechanism of action indicate that the site of action is the utero-placental complex. In fact, in pregnant rats, mice, hamsters and dogs, both plasma progesterone levels and the ineffectiveness of progesterone therapy rule out luteolysis as a basis for the activity. Moreover in hypophysectomized, ovariectomized animals whose pregnancies were maintained with proper hormonal treatments, DL 111-IT terminates pregnancy and adrenalectomy does not prevent its effect, which suggests that pituitary, ovaries and adrenals are not required for the antifertility action.

Abortifacient Agents↗